This trial is !
Search for a recruiting clinical trial for your condition
You can access this
clinical trial
if you have
Non-small Cell Lung Cancer
and you are
between 18 and 75
years old
2
3
This is an advanced phase trial assessing
the effectiveness of the new treatment before being released on the market.
Show me locations

The purpose

The purpose of this Phase II, Open-label, single arm, exploratory study is to evaluate the efficacy and the safety of Apatinib(500mg/d)with docetaxel (60 mg/m²) in advanced Non-squamous Non-small cell lung cancer after failure of first line chemotherapy.

Provided treatments

  • Drug: Apatinib
  • Drug: Docetaxel
Wondering what is the locations section for?
We will connect you to the doctor responsible for this trial and help you get more information.

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT02780778. The sponsor of the trial is Tianjin Medical University Cancer Institute and Hospital and it is looking for 20 volunteers for the current phase.
Official trial title:
Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Non-squamous and Non-small Cell Lung Cancer